{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-223676","form_type":"8-K","ticker":"SPRY","cik":"0001671858","company_name":"ARS Pharmaceuticals, Inc.","filed_at":"2024-09-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.046146+00:00","generated_at":"2026-05-31T02:27:29.739773+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ARS Pharmaceuticals amends manufacturing agreement with Renaissance Lakewood for neffy nasal spray","bullets":["Second amendment to manufacturing agreement for neffy executed September 17, 2024.","Initial term extended to five years after U.S. commercial launch and five years after EU launch, with automatic two-year renewals.","Termination provisions revised for breach, insolvency, regulatory denial/withdrawal, force majeure, and trade law violations.","Agreement covers neffy (epinephrine nasal spray) for anaphylaxis treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-223676","json":"https://secwatch.observer/filing/0001193125-24-223676.json","markdown":"https://secwatch.observer/filing/0001193125-24-223676.md","text":"https://secwatch.observer/filing/0001193125-24-223676.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671858/000119312524223676/0001193125-24-223676-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671858/000119312524223676/d834306d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T02:27:29.739773+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}